The purpose of this study is to see the safety and efficient of neoantigen reactive T cells (NRTs) in the treatment of Chinese patients with advanced gastric cancer.
Voluntarily join the study and sign the informed consent;
Age: 18-75 years old, male or female;
Subjects with advanced gastric cancer who had received systematic standard treatment before enrollment and had no effective treatment at present. (Note: The effective treatment means refer to the latest version of the "Gastric Cancer Diagnosis and Treatment Guide" issued by China's "Chinese Clinical Oncology Society".) ;
Have at least one measurable lesion according to imRECIST evaluation criteria;
Subjects infected with HBV, HCV, HIV, syphilis and tuberculosis;
Uncontrolled coronary artery disease or asthma, uncontrolled cerebrovascular disease or what the investigator considers Other diseases not included in the group;
Patients with a history of bone marrow or organ transplantation; Patients with coagulation dysfunction;
Patients with immune deficiency diseases or autoimmune diseases who are treated with immunosuppressive drugs;